Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-25T22:48:42.832Z Has data issue: false hasContentIssue false
  • English
  • Français

Opsoclonus-Myoclonus with Multiple Paraneoplastic Syndromes and VGCC Antibodies

Published online by Cambridge University Press:  02 December 2014

Colin B. Josephson ,
Ian Grant  and
Timothy Benstead
Colin B. Josephson
Affiliation:
Division of Neurology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
Ian Grant
Affiliation:
Division of Neurology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
Timothy Benstead*
Affiliation:
Division of Neurology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
*
Dalhousie University, Department of Medicine, Division of Neurology, Room 3828 Halifax Infirmary, Queen Elizabeth II Health Sciences Centre, 1796 Summer Street, Halifax, Nova Scotia, B3H 3A7, Canada
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Brief Communications
Information
Canadian Journal of Neurological Sciences , Volume 36 , Issue 4 , July 2009 , pp. 512 - 514
Copyright
Copyright © The Canadian Journal of Neurological 2009

References

1. Graus, F, Dalmau, J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol. 2007;20:732–7.Google Scholar
2. Darnell, RB, Posner, JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543–54.Google Scholar
3. Pittock, SJ, Kryzer, TJ, Lennon, VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56:715–19.CrossRefGoogle Scholar
4. Peterson, K, Rosenblum, MK, Kotanides, H, Posner, JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-yo antibody-positive patients. Neurology. 1992;42:1931–7.Google Scholar
5. Graus, F, Keime-Guibert, F, Rene, R, Benyahia, B, Ribalta, T, Ascaso, C, et al. Anti-hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.Google Scholar
6. Dalmau, J, Rosenfeld, MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7:327–40.Google Scholar
7. Nagashima, T, Mizutani, Y, Kawahara, H, Maguchi, S, Terayama, Y, Shinohara, T, et al. Anti-hu paraneoplastic syndrome presenting with brainstem-cerebellar symptoms and Lambert-Eaton myasthenic syndrome. Neuropathology. 2003;23:230–8.Google Scholar
8. Sa, G, Correia, C, Pires, M, Lopes, G. Multiple paraneoplastic syndromes occurring in the same patient: clinical, imaging and neuro-pathological documentation. Acta Med Port. 2006;19: 489–93.Google Scholar
9. Heidenreich, F, Schober, R, Brinck, U, Hartung, HP. Multiple paraneoplastic syndromes in a patient with antibodies to neuronal nucleoproteins (anti-hu). J Neurol. 1995;242:210–16.CrossRefGoogle Scholar
10. Hiasa, Y, Kunishige, M, Mitsui, T, Kondo, S, Kuriwaka, R, Shigekiyo, S, et al. Complicated paraneoplastic neurological syndromes: a report of two patients with small cell or non-small cell lung cancer. Clin Neurol Neurosurg. 2003;106:47–9.CrossRefGoogle ScholarPubMed
11. Lennon, VA, Kryzer, TJ, Griesmann, GE, O’Suilleabhain, PE, Windebank, AJ, Woppmann, A, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–74.Google Scholar
12. Fukuda, T, Motomura, M, Nakao, Y, Shiraishi, H, Yoshimura, T, Iwanaga, K, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with lambert-eaton myasthenic syndrome. Ann Neurol. 2003;53:21–8.Google Scholar
13. Lang, B, Dale, RC, Vincent, A. New autoantibody mediated disorders of the central nervous system. Curr Opin Neurol. 2003;16:351–7.Google Scholar
14. Lang, B, Newsom-Davis, J. Immunopathology of the lambert-eaton myasthenic syndrome. Springer Semin Immunopathol. 1995;17: 3–15.CrossRefGoogle ScholarPubMed
15. Motomura, M, Lang, B, Johnston, I, Palace, J, Vincent, A, Newsom-Davis, J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the lambert-eaton myasthenic syndrome. J Neurol Sci. 1997;147:35–42.Google Scholar
16. Takamori, M, Maruta, T, Komai, K. Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy. Neurosci Res. 2000;36:183–91.Google Scholar
17. Voltz, R, Carpentier, AF, Rosenfeld, MR, Posner, JB, Dalmau, J. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve. 1999;22:119–22.Google Scholar
18. Graus, F, Lang, B, Pozo-Rosich, P, Saiz, A, Casamitjana, R, Vincent, A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. 2002;59:764–6.Google Scholar
19. Liao, YJ, Safa, P, Chen, YR, Sobel, RA, Boyden, ES, Tsien, RW. Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo. Proc Natl Acad Sci USA. 2008;105: 2705–10.Google Scholar
20. Trivedi, R, Mundanthanam, G, Amyes, E, Lang, B, Vincent, A. Autoantibody screening in subacute cerebellar ataxia. Lancet. 2000;356:565–6.Google Scholar
21. Nakamura, M, Yabe, I, Sato, K, Nakano, F, Yaguchi, H, Tsuji, S, et al. Transient subacute cerebellar ataxia in a patient with lambert-eaton myasthenic syndrome after intracranial aneurysm surgery. Clin Neurol Neurosurg. 2008;110:480–3.Google Scholar
22. Clouston, PD, Saper, CB, Arbizu, T, Johnston, I, Lang, B, Newsom-Davis, J, et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the lambert-eaton myasthenic syndrome. Neurology. 1992;42:1944–50.Google Scholar
23. Lorenzoni, PJ, Scola, RH, Lang, B, Kay, CS, Teive, HA, Kowacs, PA, et al. Cerebellar ataxia in non-paraneoplastic lambert-eaton myasthenic syndrome. J Neurol Sci. 2008;270:194–6.Google Scholar
24. Mason, WP, Graus, F, Lang, B, Honnorat, J, Delattre, JY, Valldeoriola, F, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the lambert-eaton myasthenic syndrome. Brain. 1997;120 (Pt 8):1279–300.CrossRefGoogle ScholarPubMed
25. Graus, F, Vincent, A, Pozo-Rosich, P, Sabater, L, Saiz, A, Lang, B, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol. 2005; 165:166–71.Google Scholar
26. Sabater, L, Titulaer, M, Saiz, A, Verschuuren, J, Gure, AO, Graus, F. SOX1 antibodies are markers of paraneoplastic lambert-eaton myasthenic syndrome. Neurology. 2008;70:924–8.Google Scholar
27. Patel, RR, Subramaniam, RM, Mandrekar, JN, Hammack, JE, Lowe, VJ, Jett, JR. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc. 2008;83: 917–22.Google Scholar
28. Prophylactic Cranial Irradiation Overview Collaborative Group. Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission. Cochrane Database Syst Rev. 2000;(4):CD002805.Google Scholar
29. Stahl, JS. Eye movements of the murine P/Q calcium channel mutant rocker, and the impact of aging. J Neurophysiol. 2004;91: 2066–78.Google Scholar
30. Kim, HS, Chang, YH, Kim, DH, Park, SR, Han, SH, Lee, JB. Calcium uptake and release through sarcoplasmic reticulum in the inferior oblique muscles of patients with inferior oblique overaction. Yonsei Med J. 2006;47:207–13.Google Scholar
31. Gottlob, I. Nystagmus. Curr Opin Ophthalmol. 2001;12:378–83.CrossRefGoogle ScholarPubMed
32. Bataller, L, Graus, F, Saiz, A, Vilchez, JJ. Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124:437–43.CrossRefGoogle ScholarPubMed
33. Oguro-Okano, M, Griesmann, GE, Wieben, ED, Slaymaker, SJ, Snutch, TP, Lennon, VA. Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc. 1992;67:1150–9.Google Scholar
34. Roberts, A, Perera, S, Lang, B, Vincent, A, Newsom-Davis, J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature. 1985;317:737–9.CrossRefGoogle Scholar
35. Maddison, P, Newsom-Davis, J, Mills, KR, Souhami, RL. Favourable prognosis in lambert-eaton myasthenic syndrome and small-cell lung carcinoma. Lancet. 1999;353:117–18.Google Scholar